Nicht mit mir!
Ministerium für außerplanetarische Angelegenheiten/
|News & Analysis: Biotech||<!--The Page Area is EMPTY-->|
Investing in biotechnology companies is said to be like playing the slots, but hitting the jackpot can be even harder with stem-cell stocks.
Take Geron (GERN - Cramer's Take - Stockpickr - Rating), the worldwide leader in embryonic stem-cell research. It might very well cure cancer and paralysis one of these days. But the company has cost investors plenty, with its stock spiraling from $75 to $8 a share this decade.
But after researching the stem-cell industry for more than 10 years, WBB Securities analyst Stephen Brozak finally sees some payoffs on the horizon. Brozak believes that Geron's day will come and says some smaller players with commercial products on the way could bring more immediate rewards.
Brozak points to Cytori (CYTX - Cramer's Take - Stockpickr - Rating), a stem-cell company about to introduce a new medical device, as his favorite pick. Cytori's stock, down 7 cents to $5.67 Friday, trades near the middle of its 52-week range.
"If you want to make a play for stem cells here and now, you have to look at Cytori," insists Brozak, whose firm has provided consulting services to the company in the past. "We believe that they will have the first meaningful stem-cell application."
That product, a medical device that makes use of stem cells extracted from a patient's own fat, could earn regulatory approval later this year. It represents a novel breakthrough for patients undergoing breast surgery and, down the road, could bring relief to huge numbers of patients suffering from heart damage as well.
Meanwhile, Brozak stresses the importance of stock selection in the group.
"We've singled out companies with competitive advantages and significant partnerships that validate their franchises," says Brozak, whose firm has no position in stem-cell stocks themselves. In the end, "this is just as much an art as it is a science."
To watch Alix Steel's video take of this column, click here.
Stammzellen aus dem Fettgewebe lassen nach einer Brustkrebs-OP den Busen nachwachsen. Auch kranken Herzen könnte das neue Verfahren helfen.Allein in Europa muss jährlich rund 180 000 Frauen ein Teil der Brust entfernt werdenKunstbrüste aus Silikon könnten bald der Vergangenheit angehören. Mit einem neuen Verfahren haben Wissenschaftler zumindest Brustkrebspatientinnen einen neuen Busen wachsen lassen. Die 19 Teilnehmerinnen der klinischen Studie aus Japan hatten im Rahmen einer Brustkrebsbehandlung Teile ihres Busens eingebüßt.
Für ihren Versuch entnahmen Mediziner den Frauen Fettgewebe aus dem Po oder dem Bauch. In nur einer Stunde isolierten sie daraus Stammzellen und reicherten sie anschließend an. In die Brustregion injiziert, ließen die multipotenten Zellen innerhalb von sechs Monaten neues Brustgewebe sprießen.
Neue Blutgefäße fördern das Gewebewachstum
Auf welche Weise das Verfahren funktioniert, ist noch unklar. Die Forscher vermuten aber, dass die Stammzellen das Wachstum neuer Blutgefäße anregen, was die Neubildung von Gewebe fördert. Neben dem Busen ließen sich mit der Methode auch andere Körperpartien aufpolstern.
Das kalifornische Biotechnologieunternehmen Cytori Therapeutics, das das System unter dem Namen Celution auf den Markt bringt, hat in Deutschland bereits eine Zulassung erhalten. Die Markteinführung ist für das Frühjahr 2008 geplant. Allein in Europa erkranken alljährlich rund 300 000 Frauen an Brustkrebs. 60 Prozent von ihnen wird ein Teil der betroffenen Brust entfernt.
Fettstammzellen auch fürs Herz?
In weiteren Studien wollen die Forscher untersuchen, ob die Methode für die Reparatur von Herzgewebe taugt. Nachdem Versuche an Tieren mit einer Herzerkrankung vielversprechend verliefen, sollen in einem spanischen Krankenhaus Patienten mit verengten Herzkranzgefäßen mit Stammzellen aus Fettgewebe behandelt werden. In einem niederländischen Krankenhaus ist eine Studie mit Patienten geplant, die eine Herzattacke hatten.
Cytori Therapeutics and Green Hospital Supply to Commercialize Celution(TM) System in Japan
Cytori Therapeutics (Nachrichten/Aktienkurs) (NASDAQ:CYTX) (Frankfurt:XMPA) and Green Hospital Supply, Inc. (TYO:3360), have partnered to commercialize Cytori's StemSourceâ„¢ cell bank, which includes Cytori's Celutionâ„¢ System, to hospitals throughout Japan. The partnership marks the first commercial introduction of the Celutionâ„¢ System and will target a market opportunity estimated at more than $1 billion.
“Our StemSourceâ„¢ cell bank is a comprehensive automated platform that incorporates the Celutionâ„¢ System and related disposables to provide a turnkey stem and regenerative cell banking operation for almost any hospital or clinic in Japan,“ said Christopher J. Calhoun, CEO, Cytori Therapeutics.
Under the agreement, Green Hospital Supply will be the exclusive Japanese provider of both the StemSourceâ„¢ banking platform and the Celutionâ„¢ System for stem and regenerative cell banking. Cytori retains exclusive rights for both products in other countries. Revenues from all related product sales will be shared equally between Cytori and Green Hospital Supply.
“Stem cell banking is an underserved market in Japan, which is the second largest medical market in the world,“ said Kunihisa Furukawa, President, Green Hospital Supply. “Cytori's products coupled with Green Hospital Supply's market leadership in the supply, outfitting and management of more than 350 Japanese hospitals, makes this a compelling opportunity for both companies. We intend to begin introduction of these products by the first quarter of 2008, with a goal of installing cell banks in 250 hospitals by 2011.“
StemSourceâ„¢ Cell Bank
The StemSourceâ„¢ cell bank, which features Cytori's Celutionâ„¢ System, is designed to enable hospitals and clinics to become regenerative medicine centers able to remove, process, retrieve and store regenerative cells from a patient's adipose tissue. Once installed, the cell bank may be offered as an add-on banking procedure for hospital-admitted patients and in conjunction with surgeries.
Adipose Regenerative Cells
Adipose tissue is a rich and easily accessible source of stem and regenerative cells believed to be involved in the healing process. Scientific data shows that as the body ages, so too do one's regenerative cells. For this reason, early cell retrieval and storage may enhance their therapeutic potential.
Cytori will webcast an investor conference call today at 10 a.m. Eastern Daylight Time, in conjunction with the previously scheduled second quarter financial results conference call, to discuss the transaction. The webcast may be accessed at www.cytoritx.com.
Green Hospital Supply, Inc.
Green Hospital Supply, Inc. (TYO:3360) operates four businesses, which offer one-stop solutions for medical institutions in Japan to optimize their hospital management. The Total Pack System business offers solutions to meet the needs of clients to open, relocate, add and/or renovate hospital facilities. Green Hospital Supply continues the client relationships by selling medical practice materials and consumables after hospitals start operations (Medical Supply Business), and supplying meals and medical-related services (Health Care Business). The Company strengthens ties with its clients by making them business partners to further expand the spectrum of businesses, for example, launching dispensing pharmacies near hospitals (Health Care Business). www.ghs-inc.co.jp
Cytori Therapeutics is a global leader in the development and commercialization of regenerative medicine products. The company is developing therapeutic applications for its Celutionâ„¢ System to enable real-time regenerative cell therapy in conjunction with breast reconstruction surgery, cardiovascular disease, and other unmet medical needs. The Company's StemSourceâ„¢ Cell Bank, which is based on Cytori's innovative Celutionâ„¢ System, is being commercialized in Japan to hospitals and clinics to enable regenerative cell banking. www.cytoritx.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2006. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
It is with great enthusiasm that I share our recent achievements and near term goals. We are at an exciting inflection point - the commercial introduction of our Celution™ System for two major applications: reconstructive surgery and stem cell banking.
The Celution™ System was designed as a bedside device to separate and concentrate a patient's own stem and regenerative cells trapped within fat tissue so they may be re-administered in the same procedure. The commercial model will be based on system sales and recurring revenue from single-use, per-procedure consumables.
We encourage investors to measure Cytori's performance based on our achievement of the following near term milestones:
Noch ein Auszug aus dem Aktionärsbrief:
2007 is an exciting year for Cytori as we have already met many of our milestones and have several more important value driving achievements coming. We are making substantial progress across many fronts that bring the company closer to commercialization and fulfilling our goal of becoming the leading and first profitable stem cell and regenerative medicine company.
Thanks to all of our employees for their dedication, and thank you to our partners and shareholders for your continued confidence and participation in our growth.
Sonst liest es ja gar keiner. Und der Kurs gestern spiegelt die BE-Ankündigung:
bigcharts.marketwatch.com/charts/...;rand=7918&mocktick=1" style="max-width:560px" />
|Wertung||Antworten||Thema||Verfasser||letzter Verfasser||letzter Beitrag|
|Nach dem Reverse Split||BMBM||25.04.21 03:37|
|2||Cytori Therapeutics: Berichte Q1 2018||Baroh||Kursverlauf_||29.05.18 09:42|
|7||338||Cytori Therapeutics||LarsvomMars||JoeUp||02.03.15 13:05|
|11||311||Macropore biosurgery: Charttechnischer Kauf||ecki||kinu||26.05.11 20:04|